IL-15 Plus Thymosin α1 Reduces Senescent Hepatic CD8+ T Cells in Liver Cancer via PI3K/AKT Suppression
Wu F, Guo Z, Guan J, et al.
Summary
The combination of IL-15 and thymosin α1 reduced senescent CD8+ T cells in hepatocellular carcinoma through PI3K/AKT pathway suppression, suggesting a novel immunotherapeutic approach.
Clinical Significance
Expands our understanding of thymosin α1's anti-cancer immunomodulatory mechanisms in liver cancer.
Key Findings
- Thymosin α1 combined with IL-15 reduced senescent T cells in liver tumor microenvironment
- Mechanism involves PI3K/AKT signaling suppression
- Enhanced anti-tumor immune response
- Potential synergistic immunotherapy approach for hepatocellular carcinoma
Clinical Relevance
Thymosin α1's immune-modulating properties continue to show promise in oncology, extending beyond its established use in hepatitis B.
Source
相关研究
Thymosin α1-Induced IL-15/RA Secretion Restrains HIV Latency In Vitro
Thymosin α1 induced dendritic cells to secrete IL-15/retinoic acid complex, which helped restrain HI…
Thymalfasin Plus Neoadjuvant Immunochemotherapy in Locally Advanced Gastric Cancer
Neoadjuvant immunochemotherapy combined with thymalfasin showed promising results in locally advance…
Peptide Angio-3 Attenuates Pulmonary Fibrosis Via Modulation of Coagulation Factor Xa-PAR-1 Signaling Axis
Angio-3, a 10-residue peptide derived from human plasminogen kringle 3, demonstrated significant ant…
Antimicrobial Peptides Show Promise as Cancer Therapeutics: A 2026 Systematic Review
A new review in Frontiers in Medicine evaluates antimicrobial peptides (AMPs) as anticancer agents, …